A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.

NCT06481150 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Hyperoxaluria

Interventions

DRUG: Tenapanor
OTHER: Placebo

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]